|
Market Closed -
Euronext Paris
19:55:00 23/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 8.400 EUR | -6.93% |
|
+33.97% | -50.15% |
| 10-20 | Sensorion Announces Appointment of Peter Weber as Chief Medical Officer, Effective November 2, 2026 | CI |
| 10-19 | Sensorion rallies after appointment of chief medical officer |  |
| Market Cap | 86.56M 96.96M 79.96M 72.51M 136M 9.21B 138M 963M 381M 4.82B 364M 356M 15.19B | P/E 2026 * |
-2.51x | P/E 2027 * | -3.75x |
|---|---|---|---|---|---|
| Enterprise Value | 12.56M 14.07M 11.6M 10.52M 19.71M 1.34B 19.99M 140M 55.26M 699M 52.79M 51.67M 2.2B | EV / Sales 2026 * |
2.69x | EV / Sales 2027 * | 0.73x |
| Free-Float |
65.24% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ALSEN | Real-time | |
Börse Stuttgart
| RFM | Delayed | |
|
Börse Stuttgart
| RFM | Delayed | |
|
CBOE
| Real-time | ||
|
CBOE
| Real-time | ||
|
Deutsche Boerse AG
| RFM | Delayed | |
|
Boerse Muenchen
| RFM | Real-time | |
|
CBOE
| Real-time | ||
|
Boerse Muenchen
| RFM | Real-time | |
|
CBOE
| Real-time | ||
|
Tradegate
| RFM | Real-time |
| 1 day | -6.93% | ||
| 1 week | +33.97% | ||
| Current month | +15.32% | ||
| 1 month | +17.98% | ||
| 3 months | -38.12% | ||
| 6 months | -55.61% | ||
| Current year | -50.15% |
| 1 week | 6.2 |  | 10.26 |
| 1 month | 5.25 | | 10.26 |
| Current year | 5.25 | | 40.4 |
| 1 year | 5.25 | | 40.4 |
| 3 years | 5.25 | | 52 |
| 5 years | 5.25 | | 114.5 |
| 10 years | 5.25 | | 387 |
| Manager | Title | Age | Since |
|---|---|---|---|
Frédéric Chéreau
CEO | Chief Executive Officer | 59 | 01/06/2026 |
Louis Arcudi
DFI | Director of Finance/CFO | 65 | 07/10/2026 |
Bernd Schmidt
CTO | Chief Tech/Sci/R&D Officer | - | 11/12/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 09/03/2015 | |
Julien Miara
BRD | Director/Board Member | 43 | - |
Khalil Barrage
CHM | Chairman | 61 | 30/03/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 06/02/26 | Redmile Biopharma Investments III LP
| Buy | Company | 18,928,571 | 6.2956% | |
| 31/01/26 | Sofinnova Partners SAS
| Buy | Company | 10,714,285 | 3.5636% | |
| 18/04/24 | Redmile Biopharma Investments III LP
| Buy | Company | 2,781,914 | 1.0091% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.93% | +33.97% | -53.97% | -69.40% | 96.93M | |
| +2.41% | +0.29% | +42.02% | +71.57% | 64.69B | |
| -0.15% | +7.50% | +11.42% | +71.27% | 54.78B | |
| +0.57% | +4.60% | +7.71% | +90.93% | 53.49B | |
| +0.37% | +4.67% | +26.68% | +49.64% | 45.98B | |
| -1.21% | +2.32% | +21.50% | +118.33% | 42.94B | |
| -0.37% | +5.07% | +243.23% | +789.58% | 40.08B | |
| +0.05% | +0.21% | +18.26% | +58.53% | 33.52B | |
| -0.38% | +5.68% | +38.39% | +28.35% | 23.67B | |
| +1.19% | -4.98% | +26.31% | -0.76% | 23.97B | |
| Average | -0.44% | +5.57% | +38.16% | +120.81% | 38.32B | |
| Weighted average by Cap. | +0.39% | +2.74% | +46.45% | +143.56% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.66M 5.22M 4.31M 3.91M 7.31M 496M 7.42M 51.86M 20.51M 260M 19.59M 19.18M 818M | 15.92M 17.83M 14.71M 13.34M 24.97M 1.69B 25.34M 177M 70.04M 886M 66.9M 65.49M 2.79B |
| Net income | -36M -40.32M -33.25M -30.16M -56.47M -3.83B -57.3M -400M -158M -2B -151M -148M -6.32B | -28.79M -32.24M -26.59M -24.11M -45.16M -3.06B -45.82M -320M -127M -1.6B -121M -118M -5.05B |
| Net Debt | -74M -82.89M -68.35M -61.99M -116M -7.87B -118M -823M -326M -4.12B -311M -304M -12.99B | -75M -84.01M -69.28M -62.82M -118M -7.98B -119M -834M -330M -4.17B -315M -309M -13.16B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/10/26 | €8.400 | -6.93% | 14,381 |
| 22/10/26 | €9.025 | -2.01% | 26,523 |
| 21/10/26 | €9.210 | -1.06% | 49,821 |
| 20/10/26 | €9.309 | +19.04% | 102,670 |
| 19/10/26 | €7.820 | +24.72% | 55,970 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALSEN Stock
Select your edition
All financial news and data tailored to specific country editions
